Aryl-Substituted Dihydro-Pyrimidines Effecting Kinesin Eg5 as Novel Approach for Cancer Treatment

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Molecular Biology

Background:

• Cancer remains a leading cause of death, with current treatments facing challenges like severe side effects and drug resistance.
• Dihydropyrimidinones (DHPMs) are a class of compounds with a pyrimidine ring, known for their potential anticancer properties.
• Targeting the Eg5 motor protein is a validated strategy for cancer therapy, offering potent cytotoxicity with potentially reduced side effects.

Purpose of the Study:

• To review and analyze Dihydropyrimidinone derivatives substituted with a phenyl ring.
• To evaluate their antiproliferative activity through Eg5 inhibition.
• To correlate biological findings with molecular docking studies.

Main Methods:

• Literature review of DHPM derivatives with antiproliferative activity.
• Analysis of studies focusing on Eg5 inhibition by DHPMs.
• Examination of structure-activity relationships and pharmacokinetic properties.

Main Results:

• Phenyl-substituted DHPMs demonstrate significant antiproliferative effects against various cancer cell lines.
• Several compounds exhibit higher potency than established anticancer drugs.
• Inhibition of Eg5 is confirmed as the primary mechanism of action.
• Docking studies support the observed biological activities.

Conclusions:

• Phenyl-substituted DHPMs are promising anticancer agents targeting Eg5.
• These compounds offer a favorable profile regarding efficacy and side effects.
• Further development of DHPMs holds potential for novel cancer therapies.